<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180177</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-03</org_study_id>
    <nct_id>NCT03180177</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer</brief_title>
  <acronym>EHNPCTASEOC</acronym>
  <official_title>A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of HIPEC as NACT and Postoperative Chemotherapy After Interval Debulking Surgery in the Treatment of Advanced-Stage Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shu-Zhong Cui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a multi-center, prospective, randomized controlled clinical observation the
      safety and efficacy of hyperthermic intraperitoneal chemotherapy as neoadjuvant
      chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for
      advanced-stage epithelial ovarian cancer . PR/SD rate, percentage of optimal debulking
      surgery and 3-year disease-free survival is the primary end points of this project.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard treatment for epithelial ovarian cancer, tubal cancer, and primary
      peritoneal cancer is maximal cytoreductive surgery followed by intravenous chemotherapy with
      or without intraperitoneal chemotherapy (IP). Recently, the organizations of SGO and ASCO
      recommended that women with a high perioperative risk profile or a low likelihood of
      achieving cytoreduction to &lt; 1 cm of residual disease (ideally to novisible disease) should
      receive neoadjuvant chemotherapy.

      Hyperthermia promotes chemotherapy to penetrate deeper into the cancer tissue. Therefore,
      hyperthermic intraperitoneal chemotherapy (HIPEC) as neoadjuvant chemotherapy and
      postoperative chemotherapy after interval debulking surgery in the treatment of ovarian
      cancer could lead to higher response rate and better survival outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PR/SD rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>calculate the percent of partial remission (PR) plus stable disease (SD) of patients received HIPEC+NACT or NACT alone in both two arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of optimal debulking surgery</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>evaluate the percentage of optimal debulk (residual disease &lt; 1cm) after interval debulking surgery between study arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>assess disease free survival rate during 3 years in both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>assess overall survival rate during 3 years in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for morbidity and mortality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>determine percent of patients wtih Grade I-IV adverse events according to NCI criteria, Common Terminology Criteria for AE (CTCAE 4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluated according to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cancer (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for ovarian cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluated according to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">263</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks
Interval debulking surgery
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks
Interval debulking surgery
3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m^2, 43°C, 90min.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interval debulking surgery</intervention_name>
    <description>Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>IDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant chemotherapy</intervention_name>
    <description>Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 2 cycles in experimental group.
Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 3 cycles in control group.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant chemotherapy</intervention_name>
    <description>Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 2 cycles in experimental group.
Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV&gt;3 hour+ carboplatin AUC = 5-6 IV&gt;1 hour, every 3 weeks for 3 cycles in control group.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>ACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease status primary epithelial ovarian cancer, tubal cancer, and primary peritoneal
             cancer (Stage III and IV)

          -  Fagotti score by laparoscopic exploration &gt;= 6

          -  After receiving HIPEC+neoadjuvant chemotherapy (NACT) or NACT alone, the curative
             effects evaluated according to RICIST criteria is partial remission (PR) and stable
             disease (SD).

          -  Residual tumor &lt; 1cm after completion of interval debulking surgery

          -  18 &lt; Age &lt; 70 year old

          -  Expected survival &gt; 3 months

          -  Performance status: ECOG 0-1

          -  Adequate bone marrow function Hb ≥8 g/dl (After correction in case of iron deficient
             anemia) WBC ≥ 3,000/mm3, Platelet ≥ 100,000/mm3

          -  Adequate renal function Creatinine ≤ 1.5 mg/dl, and adequate hepatic function
             Bilirubin ≤ 1.5 mg/dl and AST and ALT ≤ 80 IU/L

          -  Voluntary participation after getting written informed consent.

        Exclusion Criteria:

          -  Fagotti score by laparoscopic exploration &lt; 6

          -  After receiving HIPEC+neoadjuvant chemotherapy (NACT) or NACT alone, the progression
             of disease (PD) is evaluated by doctor.

          -  Suboptimal debulking (residual tumor &gt; 1cm)

          -  Extensive adhesion in peritoneal cavity

          -  Previous History of other malignancies (except excision of skin cancer, thyroid
             cancer)

          -  Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          -  Receiving other chemotherapy, radiotherapy or immunotherapy

          -  Patients who are unsuitable candidates by doctor's decision

          -  Without given written informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuzhong Cui, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhongqiu Lin, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuzhong Cui, M.D</last_name>
    <phone>0086-138-0251-3800</phone>
    <email>cuishuzhong@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xianzi Yang, M.D</last_name>
    <phone>0086-188-9853-4167</phone>
    <email>7097359@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>shuzhong cui, M.D</last_name>
      <phone>0086-138-0251-3800</phone>
      <email>cuishuzhong@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xianzi Yang, M.D</last_name>
      <phone>0086-188-9853-4167</phone>
      <email>7097359@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>shuzhong cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Shu-Zhong Cui</investigator_full_name>
    <investigator_title>President of Affiliated Tumor Hospital of Guangzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Interval Debulking Surgery</keyword>
  <keyword>Advanced-Stage Epithelial Ovarian Cancer</keyword>
  <keyword>Postoperative Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

